Clinical Significance of FOXP3 Expression in Human Gliomas

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2013 Apr 13

PMID 23579918

Citations 11

Authors

L Wang

B Zhang

X Xu

S Zhang

X Yan

F Kong

X Feng

J Wang

Affiliations

Soon will be listed here.

Abstract

Objective: Studies have demonstrated that the transcription factor forkhead box P3 (FOXP3) is expressed not only in regulatory T cells, but also in some cancer cells. This study aims to clarify whether or not FOXP3 expression occurs in human gliomas and investigate the clinical significance of this expression in gliomas.

Methods: We detected FOXP3 protein expression in 40 glioma samples, 3 normal brain tissue samples, and 4 normal tonsil tissue samples using immunohistochemical staining and western blot. The expression of FOXP3 protein was also detected in five glioma cell lines by western blot. We also evaluated the association of FOXP3 expression with clinical pathological grades, prognosis, and recurrence.

Results: Western blot analysis showed that the expression of FOXP3 protein was upregulated in high-grade glioma (HGGS) samples compared with low-grade samples. The cell line U87 showed the highest FOXP3 expression, while U373 had the lowest expression. Immunohistochemical analysis detected FOXP3 protein in 35 out of the 40 (87.5 %) glioma samples and high levels of FOXP3 were observed in 26 out of the 27 (96.3 %) high-grade gliomas samples. Statistical analysis suggested that the upregulation of FOXP3 is significantly correlated with the histologic grade of gliomas (P < 0.05) and that patients with high expression of FOXP3 protein exhibit a poorer prognosis than those with low FOXP3 expression.

Conclusions: Our findings suggest that FOXP3 expression in glioma cells has a crucial function in the development of HGGS and is associated with the malignant biological behavior of HGGS.

Citing Articles

Immunohistochemical Analysis of PD-1 and FOXP3 in Tumor-Infiltrating Lymphocytes in Human Gliomas.

Kanagaraj P, Balasubramanian A, Suresh R, Somasundaram B, Sundaram S, Nagarajan P Cureus. 2023; 15(7):e42352.

PMID: 37621817 PMC: 10445181. DOI: 10.7759/cureus.42352.

Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma.

Adhikaree J, Moreno-Vicente J, Kaur A, Jackson A, Patel P Cells. 2020; 9(2).

PMID: 31973059 PMC: 7072315. DOI: 10.3390/cells9020263.

Immunogenetics of glioblastoma: the future of personalized patient management.

Abedalthagafi M, Barakeh D, Foshay K NPJ Precis Oncol. 2018; 2:27.

PMID: 30534602 PMC: 6279755. DOI: 10.1038/s41698-018-0070-1.

Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.

Shu C, Wang Q, Yan X, Wang J Clin Transl Oncol. 2018; 20(11):1439-1447.

PMID: 29704232 DOI: 10.1007/s12094-018-1876-6.

Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Perng P, Lim M Front Oncol. 2015; 5:153.

PMID: 26217588 PMC: 4492080. DOI: 10.3389/fonc.2015.00153.

References

Wang L, Liu R, Li W, Chen C, Katoh H, Chen G . Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16(4):336-46. PMC: 2758294. DOI: 10.1016/j.ccr.2009.08.016. View

Wang L, Su L, Wang J . Correlation between elevated FOXP3 expression and increased lymph node metastasis of gastric cancer. Chin Med J (Engl). 2011; 123(24):3545-9. View

Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W . FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007; 129(7):1275-86. PMC: 1974845. DOI: 10.1016/j.cell.2007.04.034. View

Walbert T, Mikkelsen T . Recurrent high-grade glioma: a diagnostic and therapeutic challenge. Expert Rev Neurother. 2011; 11(4):509-18. DOI: 10.1586/ern.11.37. View

Cunha L, Morari E, Nonogaki S, Soares F, Vassallo J, Ward L . Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (Sao Paulo). 2012; 67(5):483-8. PMC: 3351250. DOI: 10.6061/clinics/2012(05)13. View

Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L . FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 2007; 117(12):3765-73. PMC: 2075479. DOI: 10.1172/JCI32538. View

Ebert L, Tan B, Browning J, Svobodova S, Russell S, Kirkpatrick N . The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008; 68(8):3001-9. DOI: 10.1158/0008-5472.CAN-07-5664. View

Zhang B, Feng X, Wang J, Xu X, Lin N, Liu H . Combined antitumor effect of Ad-bFGF-siRNA and Ad-Vpr on the growth of xenograft glioma in nude mouse model. Pathol Oncol Res. 2010; 17(2):237-42. DOI: 10.1007/s12253-010-9303-5. View

Fontenot J, Rasmussen J, Williams L, Dooley J, Farr A, Rudensky A . Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005; 22(3):329-41. DOI: 10.1016/j.immuni.2005.01.016. View

10.

Jung D, Jin D, Hong S, Kim J, Shin J, Kim D . Foxp3 expression in p53-dependent DNA damage responses. J Biol Chem. 2010; 285(11):7995-8002. PMC: 2832950. DOI: 10.1074/jbc.M109.047985. View

11.

Darefsky A, King Jr J, Dubrow R . Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer. 2011; 118(8):2163-72. PMC: 3235223. DOI: 10.1002/cncr.26494. View

12.

Adams H, Avendano J, Raza S, Ziya L Gokaslan , Jallo G, Quinones-Hinojosa A . Prognostic factors and survival in primary malignant astrocytomas of the spinal cord: a population-based analysis from 1973 to 2007. Spine (Phila Pa 1976). 2012; 37(12):E727-35. PMC: 3358669. DOI: 10.1097/BRS.0b013e31824584c0. View

13.

Heimberger A, Abou-Ghazal M, Reina-Ortiz C, Yang D, Sun W, Qiao W . Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008; 14(16):5166-72. DOI: 10.1158/1078-0432.CCR-08-0320. View

14.

Zhang B, Feng X, Wang J, Xu X, Liu H, Lin N . Adenovirus-mediated delivery of bFGF small interfering RNA increases levels of connexin 43 in the glioma cell line, U251. J Exp Clin Cancer Res. 2010; 29:3. PMC: 2830951. DOI: 10.1186/1756-9966-29-3. View

15.

Held-Feindt J, Hattermann K, Sebens S, Krautwald S, Mehdorn H, Mentlein R . The transcription factor Forkhead box P3 (FoxP3) is expressed in glioma cells and associated with increased apoptosis. Exp Cell Res. 2012; 319(5):731-9. DOI: 10.1016/j.yexcr.2012.11.018. View

16.

Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J . MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer. 2008; 45(1):146-53. DOI: 10.1016/j.ejca.2008.09.002. View

17.

Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T . Foxp3 expression in human cancer cells. J Transl Med. 2008; 6:19. PMC: 2386447. DOI: 10.1186/1479-5876-6-19. View

18.

Hinz S, Pagerols-Raluy L, Oberg H, Ammerpohl O, Grussel S, Sipos B . Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 2007; 67(17):8344-50. DOI: 10.1158/0008-5472.CAN-06-3304. View

19.

Chen W, Jin W, Hardegen N, Lei K, Li L, Marinos N . Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003; 198(12):1875-86. PMC: 2194145. DOI: 10.1084/jem.20030152. View

20.

Wainwright D, Sengupta S, Han Y, Ulasov I, Lesniak M . The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One. 2010; 5(10):e15390. PMC: 2963644. DOI: 10.1371/journal.pone.0015390. View